ST. LOUIS--(BUSINESS WIRE)--DiscoveryBioMed, Inc. (DBM, Inc.) learned in recent months that it was awarded a new Phase 1 SBIR grant from the National Institutes of Health (NIH) to perform high-throughput screening (HTS)-based drug discovery and validation to discover novel small molecules that attack the secondary phase of autosomal dominant polycystic kidney disease (ADPKD). Concomitant with this news, DBM, Inc. was also approved to proceed with the Phase 2 portion of a Fast Track SBIR-funded program funded by the NIH to develop a new chemical series into a new chemical entity (NCE) and future drug to fight the initial phases of ADPKD. New future drugs from these dual programs may also have utility in attenuating secretory diarrhea and renal, urologic and other forms of cancer and fibrosis, respectively. The Phase 2 portion of the Fast Track SBIR award also continues to fund a collaboration with the Baltimore PKD Center who is conducting and will continue to conduct proof-of-concept studies in vivo in multiple and different genetic mouse models of ADPKD. Dr. Terry Watnick, M.D. is a Professor of Medicine and the Director of the Baltimore PKD Center based at the University of Maryland School of Medicine in Baltimore, MD. She is a dual PI on the SBIR award and is directing these studies along with Dr. David Huso, DVM, Ph.D. at Johns Hopkins who is Director of Mouse Models and Biobank Core C of the Baltimore PKD Center.
Help employers find you! Check out all the jobs and post your resume.
